Manali Kamdar, MD, University of Colorado Cancer Center, Aurora, CO, comments on current and emerging immunotherapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). In recent years, a large number of agents have been approved, namely tafasitamab-lenalidomide, polatuzumab vedotin with rituximab and bendamustine, loncastuximab tesirine, and CAR-T therapy in both second and third-line therapy. In addition, multiple promising agents are currently under investigation. These include bispecific antibodies such as mosunetuzumab and glofitamab, and studies have reported high efficacy with a highly manageable toxicity profile in heavily pre-treated patients. In parallel, existing CAR-T constructs are being improved and new constructs targeting new antigens are being evaluated. There is also progress in the field of R/R Hodgkin lymphoma, where CD30-directed CAR-Ts co-expressing CCR4 have shown encouraging results. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

свернуть